Targeting non-multiplying organisms as a way to develop novel antimicrobials.

[1]  P. Collignon,et al.  Staphylococcus aureus bacteraemias: time to act , 2009, The Medical journal of Australia.

[2]  I. Wiegand,et al.  Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation , 2007, Antimicrobial Agents and Chemotherapy.

[3]  C. Nacy,et al.  In search of new cures for tuberculosis. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

[4]  Jun Wang,et al.  Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties , 2007, Proceedings of the National Academy of Sciences.

[5]  R. Katneni,et al.  Central venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management , 2007, Nature Clinical Practice Nephrology.

[6]  Ying Zhang,et al.  PhoU Is a Persistence Switch Involved in Persister Formation and Tolerance to Multiple Antibiotics and Stresses in Escherichia coli , 2007, Antimicrobial Agents and Chemotherapy.

[7]  E. Swiatlo,et al.  Gene expression profiling of the response of Streptococcus pneumoniae to penicillin. , 2007, The Journal of antimicrobial chemotherapy.

[8]  P. Menéndez,et al.  The contribution of oxazolidinone frame to the biological activity of pharmaceutical drugs and natural products. , 2007, Mini reviews in medicinal chemistry.

[9]  S. Levy,et al.  Molecular Mechanisms of Antibacterial Multidrug Resistance , 2007, Cell.

[10]  M. Falagas,et al.  Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. , 2007, American journal of infection control.

[11]  S. Wutzke,et al.  Evaluation of a national programme to reduce inappropriate use of antibiotics for upper respiratory tract infections: effects on consumer awareness, beliefs, attitudes and behaviour in Australia. , 2007, Health promotion international.

[12]  Gerard D. Wright.  The antibiotic resistome: the nexus of chemical and genetic diversity , 2007, Nature Reviews Microbiology.

[13]  T. Kirikae,et al.  FtsZ: a novel target for tuberculosis drug discovery. , 2007, Current topics in medicinal chemistry.

[14]  A. Ndiaye,et al.  Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. , 2007, JAMA.

[15]  S. Keam,et al.  Daptomycin , 2012, Drugs.

[16]  K. Lewis.  Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[17]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[18]  Michael A Fischbach,et al.  New antibiotics from bacterial natural products , 2006, Nature Biotechnology.

[19]  S. Zinner,et al.  Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. , 2006, The Journal of antimicrobial chemotherapy.

[20]  F. Ausubel,et al.  Prospects for plant-derived antibacterials , 2006, Nature Biotechnology.

[21]  D. Greenhalgh,et al.  Prophylactic Intravenous Immune Globulin and Polymixin B Decrease the Incidence of Septic Episodes and Hospital Length of Stay in Severely Burned Children , 2006, Journal of burn care & research : official publication of the American Burn Association.

[22]  S. Finkel,et al.  Role of penicillin-binding protein 1b in competitive stationary-phase survival of Escherichia coli. , 2006, FEMS microbiology letters.

[23]  G. French.  Review of new guidelines for prophylaxis and treatment of MRSA infections. , 2006, British journal of hospital medicine.

[24]  S. Kamiya,et al.  In Vitro Activity of a Novel Antimicrobial Agent, TG44, for Treatment of Helicobacter pylori Infection , 2006, Antimicrobial Agents and Chemotherapy.

[25]  A. Yamaguchi,et al.  Growth Phase-Dependent Expression of Drug Exporters in Escherichia coli and Its Contribution to Drug Tolerance , 2006, Journal of bacteriology.

[26]  C. John,et al.  Therapies and vaccines for emerging bacterial infections: learning from methicillin-resistant Staphylococcus aureus. , 2006, Pediatric clinics of North America.

[27]  Arkady Khodursky,et al.  Persisters: a distinct physiological state of E. coli , 2006, BMC Microbiology.

[28]  L. Rice,et al.  Antimicrobial resistance in gram-positive bacteria. , 2006, The American journal of medicine.

[29]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[30]  Jason R. Clark,et al.  Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. , 2006, Trends in biotechnology.

[31]  M. Schmid.  Do targets limit antibiotic discovery? , 2006, Nature Biotechnology.

[32]  Mark S Butler,et al.  Natural products--the future scaffolds for novel antibiotics? , 2006, Biochemical pharmacology.

[33]  M. Mann,et al.  Robust Salmonella metabolism limits possibilities for new antimicrobials , 2006, Nature.

[34]  D. Mitchison,et al.  Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  T. Mascher,et al.  The CiaRH System of Streptococcus pneumoniae Prevents Lysis during Stress Induced by Treatment with Cell Wall Inhibitors and by Mutations in pbp2x Involved in β-Lactam Resistance , 2006, Journal of bacteriology.

[36]  M. Osburne,et al.  In Vitro Time-kill Activities of Rifalazil, Alone and in Combination with Vancomycin, against Logarithmic and Stationary Cultures of Staphylococcus aureus , 2006, The Journal of Antibiotics.

[37]  D. Hoban,et al.  The use of macrolides in treatment of upper respiratory tract infections , 2005, Current allergy and asthma reports.

[38]  Yanmin Hu,et al.  New Strategies for Antibacterial Drug Design , 2006 .

[39]  D. Livermore.  Can β‐lactams be re‐engineered to beat MRSA? , 2006 .

[40]  W. Zimmerli,et al.  Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment. , 2006, Drugs.

[41]  A. Coates,et al.  New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. , 2006, Drugs in R&D.

[42]  C. Woods.  Antimicrobial resistance: mechanisms and strategies. , 2006, Paediatric respiratory reviews.

[43]  Przemyslaw Kardas,et al.  A systematic review and meta-analysis of misuse of antibiotic therapies in the community. , 2005, International journal of antimicrobial agents.

[44]  D. Livermore,et al.  Minimising antibiotic resistance. , 2005, The Lancet. Infectious diseases.

[45]  D. Goldmann,et al.  Use of Confocal Microscopy To Analyze the Rate of Vancomycin Penetration through Staphylococcus aureus Biofilms , 2005, Antimicrobial Agents and Chemotherapy.

[46]  D. Mitchison.  The diagnosis and therapy of tuberculosis during the past 100 years. , 2005, American journal of respiratory and critical care medicine.

[47]  A. Jacq,et al.  An increased level of alternative sigma factor RpoS partially suppresses drug hypersensitivity associated with inactivation of the multidrug resistance pump AcrAB in Escherichia coli. , 2005, Research in microbiology.

[48]  Yanmin Hu,et al.  Transposon mutagenesis identifies genes which control antimicrobial drug tolerance in stationary-phase Escherichia coli. , 2005, FEMS microbiology letters.

[49]  V. Mischenko,et al.  Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. , 2005, Tuberculosis.

[50]  K. Hirota,et al.  Role for rpoS gene of Pseudomonas aeruginosa in antibiotic tolerance. , 2005, FEMS microbiology letters.

[51]  M. Smeltzer,et al.  Global Gene Expression in Staphylococcus aureus Biofilms , 2004, Journal of bacteriology.

[52]  D. Mitchison.  Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. , 2004, Seminars in respiratory and critical care medicine.

[53]  Rolf Daniel,et al.  The soil metagenome--a rich resource for the discovery of novel natural products. , 2004, Current opinion in biotechnology.

[54]  Dagmar Ringe,et al.  “Sleeping Beauty”: Quiescence in Saccharomyces cerevisiae , 2004, Microbiology and Molecular Biology Reviews.

[55]  D. Livermore.  Can better prescribing turn the tide of resistance? , 2004, Nature Reviews Microbiology.

[56]  D. Mitchison,et al.  Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[57]  D. Mitchison,et al.  The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[58]  R. Bax,et al.  The future challenges facing the development of new antimicrobial drugs , 2002, Nature Reviews Drug Discovery.

[59]  K. Bowker,et al.  Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. , 2002, International journal of antimicrobial agents.

[60]  T. File,et al.  Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. , 2002, The Journal of antimicrobial chemotherapy.

[61]  Ying Zhang,et al.  Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. , 2002, Journal of Medical Microbiology.

[62]  M. Page,et al.  Peptide Deformylase as an Antibacterial Drug Target: Target Validation and Resistance Development , 2001, Antimicrobial Agents and Chemotherapy.

[63]  F. Baquero,et al.  Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. , 2001, The Journal of antimicrobial chemotherapy.

[64]  P. Butcher,et al.  Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosisInduced by Exposure to Rifampin or Pyrazinamide , 2000, Journal of bacteriology.

[65]  K. Köhrer,et al.  Development of Resistance to Ciprofloxacin, Rifampin, and Mupirocin in Methicillin-Susceptible and -ResistantStaphylococcus aureus Isolates , 2000, Antimicrobial Agents and Chemotherapy.

[66]  P. Kimmitt,et al.  Relationships between culturability, activity and virulence in pathogenic bacteria. , 2000 .

[67]  J. Costerton,et al.  Bacterial biofilms: a common cause of persistent infections. , 1999, Science.

[68]  P. Butcher,et al.  Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. , 1998, FEMS microbiology letters.

[69]  M. Terpenning,et al.  Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. , 1993, The American journal of medicine.

[70]  E. Tuomanen.  Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. , 1986, Reviews of infectious diseases.

[71]  I. Phillips,et al.  Staphylococcus aureus bacteraemia , 1984 .

[72]  J. Worth Estes,et al.  Trends in pharmacological sciences in 1784 , 1984 .